Quick Answer
Allogene Therapeutics, Inc. reported Net Income Loss of -$190.89 million for the year ending 2025.
- Allogene Therapeutics, Inc. showed an increase of +25.9% in Net Income Loss from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$2.60 million | Q2 2018: -$134.90 million | Q3 2018: -$43.50 million | Q4 2018: -$30.51 million | Q1 2019: -$31.59 million | Q2 2019: -$41.24 million | Q3 2019: -$50.74 million | Q4 2019: -$61.03 million | Q1 2020: -$54.48 million | Q2 2020: -$60.97 million | Q3 2020: -$66.20 million | Q1 2021: -$33.02 million | Q2 2021: -$70.94 million | Q3 2021: -$78.19 million | Q1 2022: -$78.61 million | Q2 2022: -$80.29 million | Q3 2022: -$84.24 million | Q1 2023: -$99.97 million | Q2 2023: -$79.23 million | Q3 2023: -$62.29 million | Q1 2024: -$65.00 million | Q2 2024: -$66.36 million | Q3 2024: -$66.29 million | Q1 2025: -$59.73 million | Q2 2025: -$50.94 million | Q3 2025: -$41.40 million.
- Over the full 9 years of available data (2017 to 2025), Allogene Therapeutics, Inc.'s Net Income Loss has declined by 9,544,200.0%.
- Historical annual values: Fiscal year 2025: -$190.89 million | Fiscal year 2024: -$257.59 million | Fiscal year 2023: -$327.27 million | Fiscal year 2022: -$340.41 million | Fiscal year 2021: -$182.05 million | Fiscal year 2020: -$250.22 million | Fiscal year 2019: -$184.59 million | Fiscal year 2018: -$211.51 million | Fiscal year 2017: -$2.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: